Star Combo Pharma Ltd. · ASX:S66
Star Combo Pharma — Shareholder Meeting (November 2025)
16 slides from Star Combo Pharma's shareholder meeting presentation, Nov 25, 2025
Slide 1: Star Combo 2025 AGM – CEO Presentation (ASX Announcement)
STAR COMBO PHARMA LTD ABN 38 615 728 375 171 -177 Woodpark Rd Smithfield NSW 2164 P: +61 2 9756 6555 sales@starcombo.com.au 25 November 2025 ASX Announcement Star Combo 2025 AGM – CEO Presentation ____________________________________________________________________________________ Attached, please f
Slide 2: CEO Presentation – Annual General Meeting
Su Zhang For personal use only Chief Executive Officer CEO Presentation STAR COMBO PHARMA LIMITED Annual General Meeting 25 November 2025 1
Slide 3: FY25 Key results
FY25 Key results For personal use only Group Revenue increased by 6.9% year on year Commenced rebuild of new production facility Production efficiencies continue to improve Settlement of Insurance claim relating to FY 2023 factory fire Strong cash position at 30 June 2025 and continuing
Slide 4: FY Group Financial Performance
FY 25 Group Financial Performance For personal use only FY25 FY24 FY23 $000’s $000’s $000’s Note 2 Note 1 OEM Revenue $ 25,820 $23,400 $20,729 Retail Revenue $ 1,986 $2,660 $3,947 Group Revenue $27,812 $26,019 $24,700 Profit/(Loss) Before Tax $5,313 $1,001 ($3,454) Profit before asset write down $5,
Slide 5: OEM Division continues to grow Revenue
OEM Division continues to grow Revenue For personal use only FY 25 FY 24 FY 23 Full Year Full Year Full Year $000’s $000’s $000’s External Sales $25,819.5 $23,342.7 $20,729.7 Profit from Operations Note 2 $6,388.4 $1,235.0 $1,303.9 Asset Impairment Note 1 ($4,412.7) Depreciation and Amortisation ($1
Slide 6: OEM Division Update
OEM Division Update Manufacturing - OEM and Branded For personal use only OEM division has again performed strongly with increasing volume of bulk orders manufactured for new customers 41 new customer accounts have been established in the last twelve months. At the date of this report the grou
Slide 7: OEM Production efficiencies
OEM Production efficiencies For personal use only 6
Slide 8: Facilities Improvements
Facilities Improvements Building 1 (main manufacturing facility and commercial offices) For personal use only Continues to be well maintained to a high standard. Building 2+ The gummy and packaging lines are operational, and construction of the new clean room for the soft gel line is underwa
Slide 9: Retail Division break even
Retail Division break even For personal use only FY 25 FY 24 FY 23 Full Year Full Year Full Year $000’s $000’s $000’s External Sales $1,985.2 $2,660.6 $3,947.2 Profit/(Loss) from Operations $6.2 $41.9 ($216.7) Asset Impairment Depreciation and Amortisation $0.0 ($4.1) Profit /(Loss) Before Tax $6.2
Slide 10: Retail Division Update
Retail Division Update The retail division was significantly impacted by the pandemic and required some significant restructuring and For personal use only impairment of assets in FY23. Physical retail stores that the business operated in Carlingford and Ashfield in Sydney were closed in Septemb
Slide 11: Cash Position
Cash Position For personal use only Strong cash position at 30 June 2025 2025 2024 2023 $M's $M's $M's Cash and Cash Equivalents at start of Year $7.4 $9.5 $10.4 Cash and Cash Equivalents at end of Year $18.1 $7.4 $9.5 Capital Expenditure -$0.4 -$1.4 -$2.7 10
Slide 12: FY26 Q1
FY26 Q1 For personal use only During FY2026 the Group is continuing its focus on implementing and transitioning its strategy to become a leading contract manufacturer in Australia for the vitamin and health supplements sector. Retail Division continually under review Strong cash position at 30
Slide 13: Our people
Our people For personal use only People Safety Well being Our team have demonstrated As a manufacturing business, A comprehensive WHS plan agility and tenacity in guiding we are dedicated to ensuring has been implemented at the business through the we have a safe workplace. Star Combo. unfortunate f
Slide 14: Achievements & Outlook
Achievements & Outlook For personal use only FY25 Continued growth in contract Operating cash flow positive Retail Business under review Achievements manufacturing division with $18.1M in cash in bank Contract manufacturing 2026 Contract manufacturing sector remains main area of outlook remains resi
Slide 15: Thank You
Investor relations For personal use only investors@starcombo.com.au THANK YOU 10
Slide 16: Disclaimer
DISCLAIMER The information in this presentation is not a prospectus or other form of disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act) and will not be lodged with the Australian Securities and Investments Commission (ASIC). This pr
Star Combo Pharma — Shareholder Meeting (November 2025) on 6ix